PATH: Mutations Flashcards
EARLY: loss-of-funciton in TP53 and down-regulation of CKDN2A
LATE: amplification of EGFR, ERBB2, MET, cyclin D1, and cyclin E
Esophageal Adenocarcinoma
1) Amplified SOX2
2) Overexpression of Cyclin D1
3) Loss of function in TP53, E-cadherin, and NOTCH1
Esophageal Squamous Cell Carcinoma
Loss of function: APC
Gain of function: gene for Beta-catenin
(Wnt Pathway Upregulation)
Intestinal Type Gastric Adenocarcinoma
Germline Loss of APC
FAP
CDH1 mutation–> loss of E-cadherin
Diffuse Type Gastric Adenocarcinoma
1) ATI2-MLT fusion gene
2) increase MALT1 proteins
3) increase BCL-10 proteins
Constitutive expression of NF-kB.
MALT-oma
EARLY: Gain of Function in CD117 (receptor for tyrosine kinase KIT) OR Activation mutation of PDGFRA
LATE: CDKN2A or other
GIST
SDHA, SDHB–> HIF-1alpha dysregulation to increase VEGF/IGF1R transcription
Carney-Stratakis Syndrome (GIST)
NOD2 –> can’t encode protein that activate NFkB
Crohn Disease
ECM1 mutation –> uncontrolled MMP9
Ulcerative Colitis
HNFA polymorphisms
Ulcerative Colitis
Mutation/ DNA mismatch repair of MSH2 and MLH1
Hereditary Non-Polyposis Colorectal Cancer
loss-of-function STK11
Peutz-Jeghers Syndrome
EARLY: APC mutation (inactivated)
LATER: KRAS/BRAF mutation (activated)
adenomatous polyp (tubular or vilous)
EARLY: APC inactivated
LATER: KRAS/BRAF upregulated
LAST: p53 inactivated and PIK3CA upregulated
Colorectal cancer
MSI then BRAF mutation.
Sessile Serrated Adenoma
SERPINA1
alpha-1-antitryspin deficiency
C282Y mutation of HFE gene
Hereditary Hemochromatosis
ATP7B mutation
Wilson’s Disease
ADH2*1 polymorphism
Alcoholic Liver Disease predisposition (in Asians)
TNF-alpha 238 polymorphism
Alcoholic Liver Disease predisposition (in Caucasians)
EARLY: beta-catenin activation and p53 inactivation
HCC
HNF1-alpha inactivation
Hepatocellular Adenoma (very benign)
Beta-catenin activation
Hepatocellular Adenoma (very high risk for malignant transformation)
gp130 activation
inflammatory subtype hepatocellular adenoma
Activation of WNT signaling pathway.
Sporadic cases have activation of beta-catenin
Hepatoblastoma
Hemojuvelin and HAMP mutation
Type II (Juvenile) Hemochromotosis
PRSS1 gain of function (make trypsin resistant to self-inactivation)
SPINK1 loss of function (trypsin inhibitor)
CFTR loss of function
Hereditary Pancreatitis
Delta-F508 mutation of CFTR
Cystic Fibrosis
Loss of VHL tumor suppressor
Serous Pancreatic Cysts (low malignant potential)
Mutation in KRAS oncogene and TP53 and RNF43 tumor suppressors
Mucinous Pancreatic Cysts (malignant potential)
Early: KRAS activated, CDKN2A inactivated
Later: TP53 inactivated, SMAD4 inactivated
Pancreatic Adenocarcinoma
ABCG8 gene variant of sterol transporter.
Predisposition to Cholesterol stones
ERBB2 (Her2/Neu) overexpression (66%)
PBRM1 and MLL3 mutation (25%)
Gallbladder carcinoma
JAGGED1 mutation (ligand for NOTCH1)
Alagille Syndrome
MRP2 mutation
Dubin-Johnson Syndrome
UGT deficiency
Gilbert Syndrome
Fumaryl-aceto-acetase deficiency.
Tyrosinemia Type 1
Damaged/missing ornithine transcarbamylase
Ornithine Transcarbamylase Deficiency (urea cycle disorder)
Beta-glucocerebrosidase deficiency
Gaucher Disease
Glucose-6-phosphatase deficiency
von Gierke Disease
PBGD Deficiency
Acute Intermittent Porphyria